IMC-18F1 or ramucirumab DP in combination with capecitabine or capecitabine on previously treated breast cancer patients

The Canadian Partnership Against Cancer Corporation has posted a new clinical trial studying the effect of the drugs ramucirumab or IMC-18F1, combined with capecitabine or capecitibine monotherapy, on metastatic breast cancer patients. The primary outcome of this trial is progression-free survival, with adverse events, response rate, and overall survival seen as significant secondary outcome measures. As indicated, treatment with this medication "will continue until disease progression, the development of unacceptable toxicity, noncompliance or withdrawal of consent by the patient, or investigator decision" occurs. For more information on this trial, click here.